Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J0WG
|
|||
| Drug Name |
PMID27998201-Compound-1
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus infection [ICD-11: 1D92; ICD-10: B34.2] | Patented | [1] | |
| Henipavirus Encephalitis [ICD-11: 1D63] | Patented | [1] | ||
| Company |
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS PRABHAKAR, Bellur, S. ELSHABRAWY, Hatem, A
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H21N7O2
|
|||
| Canonical SMILES |
CC(C)NC1=NC(=NC(=N1)N(CC(=O)OC)C#N)NC(C)C
|
|||
| InChI |
1S/C13H21N7O2/c1-8(2)15-11-17-12(16-9(3)4)19-13(18-11)20(7-14)6-10(21)22-5/h8-9H,6H2,1-5H3,(H2,15,16,17,18,19)
|
|||
| InChIKey |
QYAYANIDXCPTDU-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin L (CTSL) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Cathepsin L (CTSL) | Target's Patent Info | [1] | |
| KEGG Pathway | Lysosome | |||
| Phagosome | ||||
| Antigen processing and presentation | ||||
| Proteoglycans in cancer | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | Endosomal/Vacuolar pathway | |||
| Collagen degradation | ||||
| Degradation of the extracellular matrix | ||||
| Trafficking and processing of endosomal TLR | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.